June 8, 2024

Biosimilar Monoclonal Antibody Market Size to Record US$ 69 Billion by 2032

The biosimilar monoclonal antibody market size is poised to grow by USD  69 billion by 2032 from USD 8.6 billion in 2022, exhibiting a CAGR of 23.2% during the forecast period 2023-2032. 

Biosimilar Monoclonal Antibody Market Size 2023 To 2032

 

Overview:

The Biosimilar Monoclonal Antibody Market is a dynamic sector within the pharmaceutical industry that focuses on the development and commercialization of biosimilar versions of monoclonal antibodies (mAbs). Monoclonal antibodies are laboratory-produced molecules engineered to mimic the immune system’s ability to fight off harmful pathogens, making them crucial in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The biosimilar segment specifically involves creating versions of existing mAbs, offering a more cost-effective alternative to their originator counterparts.

To begin with, the Biosimilar monoclonal antibody Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Reporthttps://www.precedenceresearch.com/sample/3400

Biosimilar Monoclonal Antibody Market Scope

Report Coverage Details
Growth Rate from 2023 to 2032 CAGR of 23.2%
Market Size in 2023 USD 10.55 Billion
Market Size by 2032 USD 69 Billion
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Type, By Indication, and By End User
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Risk Analytics Market Size Poised to Exceed USD 79.24 Bn By 2032

Opportunities:

The Biosimilar Monoclonal Antibody Market presents several opportunities for growth and innovation. Firstly, biosimilars have the potential to significantly reduce healthcare costs, enhancing accessibility to advanced treatments for a broader patient population. Additionally, the increasing expiration of patents for originator mAbs provides a window for biosimilar manufacturers to enter the market and compete. Collaboration and partnerships between pharmaceutical companies and regulatory agencies can streamline approval processes, expediting the market entry of biosimilar mAbs. The expanding range of therapeutic indications for mAbs also opens avenues for the development of biosimilars across diverse medical fields.

Challenges:

Despite the promising opportunities, the Biosimilar Monoclonal Antibody Market faces various challenges. Regulatory complexities and stringent approval processes demand substantial investments and extensive clinical trials, delaying the time-to-market for biosimilars. Building confidence among healthcare professionals and patients regarding the safety and efficacy of biosimilars remains a persistent challenge. Additionally, the competitive landscape poses hurdles, as establishing market share against well-established originator mAbs requires strategic pricing, effective marketing, and robust distribution networks. Technological advancements and the evolving nature of biologics also demand continuous adaptation, adding a layer of complexity to the development and manufacturing processes of biosimilar mAbs.

Top Key Players:

  • Roche
  • Novartis
  • Pfizer
  • Samsung Bioepis
  • Amgen
  • Mylan
  • Teva Pharmaceutical Industries
  • Biogen
  • Celltrion
  • Fresenius Kabi
  • Sandoz
  • Boehringer Ingelheim
  • Merck
  • Amneal Pharmaceuticals
  • Biocon

Data Sources and Methodology

To gather comprehensive insights on the Global Biosimilar monoclonal antibody Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Biosimilar monoclonal antibody Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Biosimilar monoclonal antibody market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Type

  • Adalimumab
  • Bevacizumab
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Others

By Indication

  • Oncology
  • Autoimmune diseases
  • Others

By End User

  • Hospitals
  • Cancer treatment centers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Biosimilar monoclonal antibody market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Biosimilar monoclonal antibody market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Biosimilar monoclonal antibody market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Biosimilar monoclonal antibody market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biosimilar Monoclonal Antibody Market 

5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biosimilar Monoclonal Antibody Market, By Type

8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2023-2032

8.1.1 Adalimumab

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Bevacizumab

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Infliximab

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Rituximab

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Trastuzumab

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Biosimilar Monoclonal Antibody Market, By Indication

9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2023-2032

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Autoimmune diseases

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Biosimilar Monoclonal Antibody Market, By End User 

10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Cancer treatment centers

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Biosimilar Monoclonal Antibody Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

Chapter 12. Company Profiles

12.1. Roche

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Pfizer

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Samsung Bioepis

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Amgen

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Mylan

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Teva Pharmaceutical Industries

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Biogen

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Celltrion

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Fresenius Kabi

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us:

Our team comprises a dedicated group of research analysts and management consultants who are driven by a unified vision: assisting individuals and organizations in realizing their strategic objectives, both immediate and long-term, through the provision of comprehensive research services. At Precedence Research, we have positioned ourselves to cater to the needs of a diverse range of entities, including established companies, startups, and non-profit organizations across various sectors. Our expertise extends to industries such as packaging, automotive, healthcare, chemicals and materials, industrial automation, consumer products, electronics and semiconductors, IT and telecommunications, and energy. With a wealth of experience within our ranks, our skilled analysts are equipped with extensive knowledge of the research landscape.

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *